16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
| Autor: | Thomas L. Ortel, Hannah Cohen, Maria G Tektonidou, Doruk Erkan, Anisur Rahman, David J. Williams, Jason S. Knight, David A. Isenberg, Rohan Willis, Alí Duarte-García, Maria José Cuadrado, Jane E. Salmon, Scott C. Woller, Danieli Andrade |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
030204 cardiovascular system & hematology Thrombophilia direct oral anticoagulants 03 medical and health sciences 0302 clinical medicine Rheumatology Antiphospholipid syndrome complement inhibition Vitamin D and neurology Medicine Humans biologics Intensive care medicine 030203 arthritis & rheumatology anti-β2-glycoprotein I peptides business.industry potential new players Anticoagulants Hydroxychloroquine Thrombosis Congresses as Topic medicine.disease Antiphospholipid Syndrome Belimumab Clinical research Papers Factor Xa Antibodies Antiphospholipid Rituximab business medicine.drug |
| Zdroj: | Lupus |
| ISSN: | 1477-0962 0961-2033 |
| Popis: | Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive therapies (hydroxychloroquine, statins and vitamin D), targeted treatment including rituximab, belimumab, and anti-TNF agents, complement inhibition and drugs based on peptides of beta-2-glycoprotein I. In addition, the report summarises potential new players, including coenzyme Q10, adenosine receptor agonists and adenosine potentiation. In each case, the report provides recommendations for clinicians, based on the current state of the art, and suggests a clinical research agenda. The initiation and development of appropriate clinical studies requires a focus on devising suitable outcome measures, including a disease activity index, an optimal damage index, and a specific quality of life index. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|